Geron (GERN) closed at $1.17 on October 16, 2026, down 4.9% from the previous close, on volume of 3,850,815 shares (30-day average 9,275,069).
Data as of October 16, 2026.
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Tue, 13-Oct 2:52 PM ET)
Business Wire (Mon, 12-Oct 12:14 PM ET)
Globe Newswire (Mon, 12-Oct 8:03 AM ET)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 18-Sep 4:01 PM ET)
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
PRNewswire (Wed, 2-Sep 1:37 PM ET)
Geron to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Geron Delivers Strong Revenue Growth with RYTELO in Q2 2026 as Cash Position Remains Solid
Market Chameleon (Wed, 5-Aug 7:46 AM ET)
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Market Chameleon (Mon, 12-Jan 6:53 AM ET)
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Geron trades on the NASDAQ stock market under the symbol GERN.
As of October 19, 2026, GERN stock price climbed to $1.19 with 933,832 million shares trading.
GERN has a beta of 1.73, meaning it tends to be more sensitive to market movements. GERN has a correlation of 0.15 to the broad based SPY ETF.
GERN has a market cap of $764.54 million. This is considered a Small Cap stock.
Last quarter Geron reported $57 million in Revenue and -$.02 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.
In the last 3 years, GERN traded as high as $5.34 and as low as $1.04.
The top ETF exchange traded funds that GERN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
GERN has underperformed the market in the last year with a price return of -3.3% while the SPY ETF gained +17.5%. GERN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.2% and -0.8%, respectively, while the SPY returned +2.7% and -0.1%, respectively.
GERN support price is $1.14 and resistance is $1.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GERN shares will trade within this expected range on the day.